Phase 1b trial of avelumab, an anti-PD-L1 antibody, in advanced gastric or gastroesophageal junction cancer | Dr Hendrik-Tobias Arkenau at ECC 2015

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b clinical trial that evaluated the safety and clinical activity of avelumab, a fully human anti-PD-L1 IgG1 antibody, for the treatment of patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews